Astrocyte Pharmaceuticals Inc.


Astrocyte Pharmaceuticals is a pre-IND neuroscience drug development company with a novel small molecule drug for the treatment of stroke, traumatic brain injury and concussion. The company has demonstrated significant neuroprotective efficacy in mouse, rat, pig, and non-human primate models, with acute treatment administered as late as 24 hours post injury. The company has raised ~$9M in public and private investment.

Video Pitch

Management Team

Co-Founder and CEO

William Korinek

Previously VP of Worldwide R&D Business Operations at Pfizer; Managed annual investment business plans from all of Pfizer’s Research Units and functional Partner Lines and the setting of annual investment and budget targets; Championed and secured $24M in capital to overall Pfizer’s Project and Resource Planning, which he led and successfully implemented over 2011-2014; 5 year biopharma strategist as Engagement Manager at L.E.K. Consulting

VP of Research

Theodore Liston

Formerly a Pfizer Vice-President in Discovery Research and in Pharmacokinetics, Dynamics and Metabolism (PDM) leading the operations of the largest PDM site, and guiding the work of >200 scientists; central roles in the successful discovery and clinical advancement of well over 100 diverse compounds targeting therapeutic endpoints in neuroscience and other TAs.

Co-Founder and Advisor

James Lechleiter

Professor of Cellular and Structural Biology at the University of Texas Health Science Center at San Antonio (UTHSCSA) Research focus on the molecular and cellular mechanisms of protection during acute brain injury, ischemic stress, and aging Sole inventor on US Patent #8,618,074 (licensed to Astrocyte) International leader in Ca+2 signaling; discovered intracellular spiral Ca+2 waves Over 50 peer-reviewed publications

Head of CMC

Russell Poe

Pharmaceutical professional with 20 years of development experience including 10 years of leading small molecule Chemistry and Manufacturing Controls (CMC) multidisciplinary teams and core member of drug candidate teams. Extensive drug development experience across all phases of Research – progressing new chemical entities, managing CMO vendors, regulatory dossiers, drug substance and product characterization, risk assessment, etc.

Head of Non-Clinical Safety Assessment

Stanley Roberts

Over 30 years in scientific and management positions in toxicology, drug metabolism, pharmacokinetics and drug development within large (Sandoz, Abbott & Pfizer) and small (CovX) pharma companies. Planned and conducted a wide variety of preclinical studies at CROs, totaling well over $30 million dollars in the last 10 years. Authored >400 proprietary final reports and making major contributions to numerous regulatory strategies/submissions